Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 11:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 6,316 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelofibrosis
Interventions
SB1518
Drug
Lead sponsor
S*BIO
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Chicago, Illinois • Houston, Texas • Seattle, Washington
Conditions
Primary Fibromyalgia
Interventions
Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
13 Years to 17 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Fresno, California + 24 more
Conditions
Migraine Headaches, Nausea, Restlessness
Interventions
Haloperidol, Metoclopramide 10mg, Diphenhydramine
Drug
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Portsmouth, Virginia
Conditions
Migraine
Interventions
AMG 333, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Cognitive Impairments, RRSO
Interventions
lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Generalized Anxiety Disorder
Interventions
CBT, Usual Care
Behavioral · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
60 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hypertension
Interventions
Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
etoposide, topotecan hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Iowa City, Iowa • Baltimore, Maryland • Camden, New Jersey + 2 more
Conditions
Lung Cancer
Interventions
cytology specimen collection procedure, immunoenzyme technique, study of high risk factors
Other · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
5
States / cities
Tampa, Florida • Des Moines, Iowa • Hackensack, New Jersey + 2 more
Conditions
Migraine, Medication Adherence
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Tampa, Florida • St Louis, Missouri • Cleveland, Ohio
Conditions
Primary Immune Deficiency
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
Bethesda, Maryland • Ann Arbor, Michigan
Conditions
Breast Cancer
Interventions
Imaging Drug FluorThanatrace (FTT)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Ovarian Cancer, Breast Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer
Interventions
Carboplatin, Olaparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Immunoglobulin A (IgA) Nephropathy
Interventions
PS-002
Genetic
Lead sponsor
Purespring Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Miami, Florida • Baltimore, Maryland
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of Patients With Immune Function Abnormalities

NCT00128973
Conditions
Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID), Leukocyte Adhesion Deficiency 1 (LAD), Graft Versus Host Disease (cGvHD)
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
3,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Electronic Health Record Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Completed Not applicable Interventional Results available

Validation of Indiana's Early Evaluation Hub System

NCT06586788
Conditions
Autism
Interventions
Eyelink Portable Duo, Integrated PCP Diagnosis and Eye-tracking Biomarker
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
14 Months to 48 Months
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Anderson, Indiana • Batesville, Indiana • Indianapolis, Indiana + 4 more
Conditions
Pancreatic Cancer
Interventions
microarray analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Belinostat, Carfilzomib, Copanlisib Hydrochloride, Daratumumab, Fludeoxyglucose F-18, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nivolumab, Obinutuzumab, Pembrolizumab, Positron Emission Tomography, Rituximab, Romidepsin, Saline, Trastuzumab
Drug · Biological · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Ovarian Reserve After Cancer: Longitudinal Effects

NCT02467231
Conditions
Effects of Chemotherapy, Premature Ovarian Failure
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
11 Years to 35 Years · Female only
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Results available

DDBT Adapted Problem Solving Treatment for Primary Care

NCT03514394
Conditions
Depression, PTSD
Interventions
Usual Care, Modified Behavioral Activation (Task Sharing)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Hardin, Montana
Conditions
Primary Peritoneal Cavity Cancer, Stage I Endometrial Carcinoma, Stage I Ovarian Epithelial Cancer, Stage IA Cervical Cancer, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage II Ovarian Epithelial Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Endometrial Carcinoma, Stage IV Ovarian Epithelial Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions
EF5
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Refractory Migraine
Interventions
Lidocaine hydrochloride, Methylprednisolone sodium succinate
Drug
Lead sponsor
Cooper Norcross Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Camden, New Jersey
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
Interventions
Clofarabine 40mg/m^2, Idarubicin 10mg/m^2, Ara-C 0.75 g/m^2, Clofarabine 22.5mg/m^2, Ara-C 1 g/m^2, Idarubicin 6 mg/m^2
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 59 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Houston, Texas